Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14923
Abstract: To conduct a post hoc analysis to explore indices of hepatic steatosis/fibrosis and cardiorenal outcomes in the VERTIS CV study. read more here.
Keywords: cardiorenal outcomes; steatosis fibrosis; liver steatosis; indices liver ... See more keywords